{"preliminary_commentary":{"by_channel":{"x_thread":138,"youtube":129,"podcast":89,"bluesky_thread":3,"x_video":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04975308\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"EMBER-3","nct_id":"NCT04975308","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ember-3-nct04975308. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"EMBER-3","arms":[{"description":"Participants received Imlunestrant 400 milligrams (mg) orally once daily on days 1 to 28 of a 28-day cycle, until disease progression or a criterion for discontinuation were met.","label":"Arm A: Imlunestrant","type":"EXPERIMENTAL"},{"description":"Participants received the investigator's choice of endocrine therapy, either exemestane 25 mg administered orally once daily on days 1 to 28 of a 28-day cycle, or Fulvestrant 500 mg intramuscularly on days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond, until disease progression or a criterion for discontinuation was met.","label":"Arm B: Investigator's Choice of Endocrine Therapy","type":"EXPERIMENTAL"},{"description":"Participants received Imlunestrant 400 mg orally once daily on Days 1 to 28 of a 28-day cycle, plus Abemaciclib 150 mg orally twice daily on Days 1 to 28 of a 28-day cycle, until disease progression or a criterion for discontinuation was met.","label":"Arm C: Imlunestrant + Abemaciclib","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-08","type":"ESTIMATED"},"conditions":["Breast Neoplasms","Neoplasm Metastasis"],"enrollment":{"count":874,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Imlunestrant","otherNames":["LY3484356"],"type":"DRUG"},{"name":"Exemestane","otherNames":[],"type":"DRUG"},{"name":"Fulvestrant","otherNames":[],"type":"DRUG"},{"name":"Abemaciclib","otherNames":["LY2835219"],"type":"DRUG"}],"last_update":"2026-07-22","lead_sponsor":"Eli Lilly and Company","official_title":"EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-06-24","type":"ACTUAL"},"primary_outcomes":[{"measure":"Investigator-assessed Progression Free Survival (PFS) (Between Arm A and Arm B)","timeFrame":"Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)"},{"measure":"Investigator-assessed PFS (Between Arm C and Arm A)","timeFrame":"Randomization to the date of first documented progression of disease or death from any cause (up to 26 months)"},{"measure":"Investigator-assessed PFS in the Estrogen Receptor 1 (ESR1)-Mutation Detected Population (Between Arm A and Arm B)","timeFrame":"Randomization to the date of first documented progression of disease or death from any cause (up to 28 months)"}],"references":[{"citation":"Jhaveri KL, Neven P, Casalnuovo ML, Kim SB, Tokunaga E, Aftimos P, Saura C, O'Shaughnessy J, Harbeck N, Carey LA, Curigliano G, Llombart-Cussac A, Lim E, Garcia Tinoco ML, Sohn J, Mattar A, Zhang Q, Huang CS, Hung CC, Martinez Rodriguez JL, Ruiz Borrego M, Nakamura R, Pradhan KR, Cramer von Laue C, Barrett E, Cao S, Wang XA, Smyth LM, Bidard FC; EMBER-3 Study Group. Imlunestrant with or without Abemaciclib in Advanced Breast Cancer. N Engl J Med. 2025 Mar 27;392(12):1189-1202. doi: 10.1056/NEJMoa2410858. Epub 2024 Dec 11.","pmid":"39660834","type":"DERIVED"}],"start_date":{"date":"2021-10-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer","url":"https://clinicaltrials.gov/study/NCT04975308"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ember-3-nct04975308"}